Pathkey.AI (ASX:PKY), an Australian artificial intelligence technology firm, announced the execution of a strategic services agreement with Imunexus Therapeutics.
The commercial contract, valued at up to $100,000 plus GST, marks a pivotal advancement in Pathkey’s commercialisation strategy by converting its proprietary TrialKey platform into a revenue-generating asset.
The engagement provides immediate financial validation for the company’s AI capabilities, with an initial $25,000 plus GST payable upon execution.
The remaining $75,000 is structured in three equal tranches, contingent upon Imunexus achieving specific milestones and future capital raisings.
The partnership serves as a critical real-world validation of the TrialKey platform, as Imunexus integrates the technology into its live clinical development and capital-raising workflows.
The platform is being utilised for high-value applications, including the assessment of development risks, the optimisation of early-phase clinical trial designs, and the benchmarking of pipeline assets against extensive global datasets.
While the agreement features an initial one-year term, it is designed to establish a foundation for expanded engagement and follow-on work.
By securing this contract, Pathkey positions itself for sustainable growth, with the deal expected to contribute to revenue throughout FY26 and FY27.